Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 7 of 7 results for norethisterone

  1. Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

    Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA832

  2. Linzagolix for treating symptoms of endometriosis [ID6357]

    In development [GID-TA11376] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  3. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [ID3982]

    In development [GID-TA10873] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

    Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.

    Technology appraisal guidance
    Published
    14 August 2024
    View recommendations

    Sections for TA996

  5. Past appeals and decisions

    degarelix depot [ID590] 12 November 2014 TA832 Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of...

  6. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.

  7. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.